Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation

Acta Pharmacologica Sinica

Volumn 32, Issue 5, 2011, Pages 591-600

  Zhong, Xing ^a   Xiu, Ling Ling ^a   Wei, Guo Hong ^a   Liu, Yuan Yuan ^a   Su, Lei ^a   Cao, Xiao Pei ^a   Li, Yan Bing ^a   Xiao, Hai Peng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

AMPK; bezafibrate; eNOS; MC3T3 E1 cell; osteoblast; PPAR ; PPAR

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ALKALINE PHOSPHATASE; BEZAFIBRATE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

3T3 CELLS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BEZAFIBRATE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OSTEOBLASTS; PHOSPHORYLATION; PPAR-BETA; TIME FACTORS;

EID: 79959724249     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.15     Document Type: Article

References (43)

1. Chan GK, Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002; 48: 62-71. (Pubitemid 34195721)
2. Dennison EM, Syddall HE, Aihie Sayer A, Martin HJ, Cooper C. Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study. QJM 2007; 100: 297-303. (Pubitemid 47062907)
3. Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS, et al. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int 2005; 16: 1975-81.
4. Lorincz C, Reimer RA, Boyd SK, Zernicke RF. High-fat, sucrose diet impairs geometrical and mechanical properties of cortical bone in mice. Br J Nutr 2010; 103: 1302-8.
5. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMGCoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-10. (Pubitemid 30422037)
6. Still K, Grabowski P, Mackie I, Perry M, Bishop N. The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 2008; 83: 285-92.
7. Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta 2003; 1632: 80-9. (Pubitemid 36628119)
8. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.
9. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001; 52: 290-8. (Pubitemid 33000406)
10. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NFkappaB activation through AMP-activated protein kinase activation. Life Sci 2008; 82: 884-91.
11. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 2006; 341: 973-8. (Pubitemid 43221761)
12. Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 2007; 282: 19313-20. (Pubitemid 47100082)
13. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol 2007; 8: 51-62.
14. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP- 2 expression. Biochem Biophys Res Commun 2008; 375: 414-9.
15. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, Saxon L, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone 2010; 47: 309-19.
16. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003; 278: 31629-39.
17. Wimalawansa SJ. Nitric oxide and bone. Ann N Y Acad Sci 2010; 1192: 391-403.
18. Grassi F, Fan X, Rahnert J, Weitzmann MN, Pacifici R, Nanes MS, et al. Bone re/modeling is more dynamic in the endothelial nitric oxide synthase(-/-) mouse. Endocrinology 2006; 147: 4392-9. (Pubitemid 44268390)
19. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 1992; 7: 683-92.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
21. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 1998; 67: 821-55.
22. Riancho JA, Salas E, Zarrabeitia MT, Olmos JM, Amado JA, Fernandez- Luna JL, et al. Expression and functional role of nitric oxide synthase in osteoblast-like cells. J Bone Miner Res 1995; 10: 439-46.
23. Lin IC, Smartt JM Jr, Nah HD, Ischiropoulos H, Kirschner RE. Nitric oxide stimulates proliferation and differentiation of fetal calvarial osteoblasts and dural cells. Plast Reconstr Surg 2008; 121: 1554-66. (Pubitemid 351642705)
24. Kanamaru Y, Takada T, Saura R, Mizuno K. Effect of nitric oxide on mouse clonal osteogenic cell, MC3T3-E1, proliferation in vitro. Kobe J Med Sci 2001; 47: 1-11. (Pubitemid 32862066)
25. Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, et al. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 2009; 9: 10-22.
26. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50. (Pubitemid 30127149)
27. Boo YC, Sorescu G, Boyd N, Shiojima I, Walsh K, Du J, et al. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J Biol Chem 2002; 277: 3388-96. (Pubitemid 34953207)
28. Fan X, Rahnert JA, Murphy TC, Nanes MS, Greenfield EM, Rubin J. Response to mechanical strain in an immortalized pre-osteoblast cell is dependent on ERK1/2. J Cell Physiol 2006; 207: 454-60.
29. Koyama A, Otsuka E, Inoue A, Hirose S, Hagiwara H. Nitric oxide accelerates the ascorbic acid-induced osteoblastic differentiation of mouse stromal ST2 cells by stimulating the production of prostaglandin E2. Eur J Pharmacol 2000; 391: 225-31. (Pubitemid 30154088)
30. Shirwany NA, Zou MH. AMPK in cardiovascular health and disease. Acta Pharmacol Sin 2010; 31: 1075-84.
31. Wang Y, Yang Q, Yan JT, Zhao C, Cianflone K, Wang DW. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells. Atherosclerosis 2006; 187: 265-73. (Pubitemid 43977770)
32. Nakajima T, Tanaka N, Sugiyama E, Kamijo Y, Hara A, Hu R, et al. Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice. Biochem Pharmacol 2008; 76: 108-19.
33. Poirier H, Niot I, Monnot MC, Braissant O, Meunier-Durmort C, Costet P, et al. Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochem J 2001; 355: 481-8. (Pubitemid 32397809)
34. Jackson SM, Demer LL. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 2000; 471: 119-24. (Pubitemid 30173305)
35. Rosen V. BMP2 signaling in bone development and repair. Cytokine Growth Factor Rev 2009; 20: 475-80.
36. Komori T. Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem 2005; 95: 445-53. (Pubitemid 41420175)
37. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab 2009; 296: E139-46.
38. Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006; 58: 3-18. (Pubitemid 43041991)
39. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB, Gomez-Alonso C, Cannata-Andia JB. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008; 19: 1161-6.
40. Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol 2000; 20: 2346-8.
41. Adami S, Braga V, Gatti D. Association between bone mineral density and serum lipids in men. JAMA 2001; 286: 791-2. (Pubitemid 33015570)
42. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4: 368-81.
43. Fiore CE, Pennisi P, Pulvirenti I, Francucci CM. Bisphosphonates and atherosclerosis. J Endocrinol Invest 2009; 32: 38-43.